Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.93 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.79 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.74 |
| ▸ | HRH2 | P25021 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224745 | 0.89 | TAAR1 (1.00) | HRH3TAAR1HRH4 | |
| SCHEMBL8963886 | 0.84 | HRH3 (0.75) | HRH3HRH4HRH2 | |
| Proxyfan SCHEMBL15929504 | 0.80 | HRH3 (1.00) | HRH3TAAR1HRH4 | |
| SCHEMBL8964986 | 0.80 | HRH3 (0.79) | HRH3HRH4HRH2 | |
| SCHEMBL1034848 | 0.79 | HRH3 (1.00) | HRH3TAAR1HRH4 | |
| SCHEMBL8963957 | 0.78 | HRH3 (0.80) | HRH3HRH4HRH2 | |
| SCHEMBL14415974 | 0.76 | HRH4 (1.00) | HRH3TAAR1HRH4HRH2 | |
| SCHEMBL27871764 | 0.76 | TAAR1 (0.65) | HRH3TAAR1HRH4 | |
| Proxyfan SCHEMBL29462311 | 0.75 | HRH3 (0.87) | HRH3HRH4 | |
| SCHEMBL8963903 | 0.75 | HRH3 (0.73) | HRH3TAAR1HRH4HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109890795-A | The imdazole derivatives that new 5- replaces | 拜耳作物科学股份公司 | 2019-06-14 | — | — | CN | disclosed |
| EP-2382223-A1 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS | Novartis AG (CH) | 2011-11-02 | — | — | EP | disclosed |
| US-20110257131-A1 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS | NOVARTIS AG (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257131-A1 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS | NOVARTIS AG (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257131-A1 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS | NOVARTIS AG (CH) | 2011-10-20 | — | — | US | disclosed |
| WO-2010076258-A1 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS | NOVARTIS AG (CH) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257131-A1 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS | PTEN, INPP5D, PPIP5K2 | HRH3 335/4885TAAR1 3483/4885HRH4 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.